Allocation to SGLT-2 inhibitors reduced the risk of severe hypoglycaemia by 13% (0.87, 0.79-0.97; 1484 events), again without heterogeneity of effects in the different patient groups studied (all het test p>0.05: Supplemental Figure 6). Here, SLC5A2 is linked to Hypoglycemia.